drugset / Trial / NCT04825678

A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

NCT04825678

Phase 4 Completed 240 enrolled Amgen
NaSingle-groupOpen-labelHealth-services research

Summary

The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.

Timeline

Start
2021-06-11
Primary completion
2023-09-28
Completion
2023-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Erenumab Monoclonal antibody Subcutaneous

Indications